Sun Pharmaceuticals
India is among the top 10 pharmaceutical exporting countries with its share of the global market on the rise compared to the previous 5 years.
Sun Pharmaceuticals is the largest pharmaceutical company from India and the fifth largest specialty generic company in the world. It has capabilities across dosage forms like injectables, sprays, ointments, creams, liquids, tablets, and capsules. Its businesses include producing generics, branded generics, speciality, over the counter (OTC) products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and intermediates in the full range of dosage forms. It also produces specialty APIs. In FY 2020-21, India branded generics contributed the most to company’s sales with 31% share, followed by US business at 30% share.
Company Website: www.sunpharma.com
Sun Pharma – Reaching People. Touching Lives.
| 2022 |
In May 2022, Sun Pharmaceutical Industries Limited through one of its wholly owned subsidiaries plans to launch Bempedoic Acid under the brand name Brillo, in India for reducing low-density lipoprotein (LDL) cholesterol. In January 2022, Sun Pharma launches PrCEQUA (cyclosporine ophthalmic solution 0.09% w/v), the first dry eye treatment with nanomicellar (NCELL) technology, in Canada. |
| 2021 |
In September 2021, with the launch of Revital NXT, Sun Pharma Consumer Healthcare, a division of Sun Pharmaceutical Industries Ltd., announced its entry into the nutrition bar category in India. Revital NXT, is a brand extension of Revital H, a health supplement. In June 2021, Sun Pharmaceuticals acquired the patent license for Dapagliflozin from AstraZeneca. The company will distribute and promote the drug under the brand name ‘Oxra’. In May 2021, the company entered a royalty-free, non-exclusive licensing agreement with Eli Lilly and Company to expand access to the COVID-19 drug, Baricitinib. The company will manufacture and distribute the drug in India. https://www.ndtv.com/business/coronavirus-medicine-covid-19-infection-drug-news-sun-pharma-gains-on-agreement-with-eli-lilly-to-make-baricitinib-in-india-2438740In March 2021, Sun Pharmaceuticals acquired a 12.5% stake in Australia-based WRS Bioproducts for US$ 1.5 million. In February 2021, the company launched a website for its long-term care portfolio in the US, highlighting the efficacy and safety profile for each product. In February 2021, it introduced Brivaracetam, an anti-epileptic drug, in multiple dosage forms, a day after the patent expiry. This drug was developed by UCB, a Belgian-based firm. |
| 2020 | Sun Pharma announced five-year sustained efficacy and safety results for ILUMYA in patients with moderate-to-severe plaque psoriasis |
| 2019 | Sun Pharma and AstraZeneca entered into a license agreement for novel oncology products in China Sun Pharma’s arm, Sun Pharmaceutical Industries, acquired its remaining 3.04% stake in PJSC Biosintez, Russia Sun Pharma and China Medical System Holdings entered into licensing agreement for generic products in Mainland China |
| 2018 | Sun Pharma to acquire Pola Pharma in Japan |
| 2018 | Sales of Rs 27,956 crore (US$ 4 billion) in FY18; Announced acquisition of US-based speciality pharmaceutical company Avenue Therapeutics for Rs 1502.635 crore (US$ 215 million) |
| 2017 | Agreement signed with National Institute of Virology, India to fight Zika, Chikungunya and Dengue |
| 2013 | Became world’s fifth largest specialty generic pharmaceutical company with acquisition of Ranbaxy |
| 2000 | Acquired Pradeep Drug Company |
| 1997 | First international acquisition with Caraco Pharmaceutical Laboratories, USA |
| 1996 | Sales network expanded across 24 countries |
| 1994 | Launched initial public offer (IPO) |
| 1989 | Introduced gastroenterology products in India |
| 1983 | Established with a portfolio of five psychiatry products |
- World’s fifth largest specialty generic pharmaceutical company
- Serves over 150 markets across the world
- More than 2,000 marketed products
- More than 40 manufacturing sites
- In FY21, the company’s total income reached US$ 4.5 billion
- Gross sales for Q1 FY22 stood at Rs. 96,694 million (US$ 1.31 billion), up 29% YoY.
Partners
